Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Anastasia XagaraLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0001-8104-1514
Maria GoulielmakiCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Ave., 11522 Athens, Greece.ORCID 0000-0001-9596-5048
Sotirios P FortisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Ave., 11522 Athens, Greece.
Alexandros KokkalisDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Evangelia ChantzaraDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
George ChristodoulopoulosDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Ioannis SamarasDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Emmanouil SaloustrosDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Konstantinos TsapakidisDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.ORCID 0000-0002-8994-6067
Vasileios PapadopoulosDepartment of Medical Oncology, University General Hospital of Larissa, 41110 Larissa, Greece.
Ioannis S PaterasSecond Department of Pathology, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens, 15772 Athens, Greece.
Vasilis GeorgouliasFirst Department of Medical Oncology, Metropolitan General Hospital, 15562 Athens, Greece.ORCID 0000-0003-2218-2522
Constantin N BaxevanisCancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Ave., 11522 Athens, Greece.ORCID 0000-0003-0324-7378
Athanasios KotsakisLaboratory of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41110 Larissa, Greece.ORCID 0000-0002-5530-6774
Funding
European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RE-SEARCH-CREATE-INNOVATE Τ2ΕΔΚ-02218
6 · The paper itself
Abstract
T-cell-mediated anti-tumoral responses may have significant clinical relevance as a biomarker for response to immunotherapy. The value of peripheral blood pre-existing tumor antigen-specific T cells (PreI
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients. · full record | OpenQuestion